Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer
Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
Limited agents are optional after standard first and second line treatment for mCRC. Only
Regorafenib and Fruquintinib are approved in China. PFS of these targeted drugs are not very
long. Pemetrexed has shown significant efficacy in advanced lung cancer regarding PFS and OS
with controllable toxicity. TAS-102 has been used in colorectal cancer with promising
outcomes. Bevacizumab is also an important monoclonal antibody which could make benefits in
treated patients. This study is aimed to explore the efficacy, safety in advanced colorectal
cancer failed to standard therapy in Chinese population.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University